ADRB3 and peripheral arterial disease: Repurposing β3AR agonists as therapeutic agents for PAD and DFUs is a low-risk, non-invasive, cost-effective option that can complement current approaches to PAD and DFU, with the potential to improve tissue healing and reduce the demand for surgical interventions—the single biggest driver for non-traumatic major and minor amputations [6].